Quinine Sulphate Microparticles as Treatment for Leishmaniasis
Joint Authors
Amponsah, Seth Kwabena
Allotey-Babington, Grace Lovia
Nettey, Thomas
Sasu, Clement
Nettey, Henry
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-04-30
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
Leishmaniasis is a neglected tropical disease caused by the Leishmania parasite and transmitted by the female phlebotomine sandfly.
The disease can affect the skin (least fatal) or internal organs (most fatal).
Current treatment options for leishmaniasis have a number of adverse effects, and there appears to be resistance by the protozoan parasite (Leishmania spp.).
Reports suggest that quinine sulphate, not indicated for leishmaniasis, is effective in killing the Leishmania parasite.
Indeed, the efficacy of any drug is dependent on the concentration at the target site, which is also almost dependent on drug formulation.
The current study assessed the pharmacokinetic profile of the microparticulate formulation of quinine sulphate and its in vitro and in vivo efficacy against Leishmania donovani.
Methods.
Quinine sulphate was encapsulated in bovine serum albumin by the spray-drying method.
Quinine sulphate microparticles were evaluated for size, zeta potential, drug content, encapsulation efficiency, and in vitro release properties.
Afterwards, the pharmacokinetic characteristics of quinine sulphate microparticles were estimated and in vivo efficacy studies were also conducted.
Results.
The size range of the quinine sulphate microparticles was between 2.0 and 5.0 µm.
Microparticles had an average zeta potential of −35.2 mV and an encapsulation efficiency of 94.5%.
Also, Cmax, t1/2, and AUC were all significantly desirable for quinine sulphate microparticles compared to the drug powder.
Quinine sulphate microparticles significantly reduced parasite load in rat organs than amphotericin B.
Conclusion.
Overall, quinine sulphate microparticles had better pharmacokinetic profile and showed higher efficacy against Leishmania donovani parasites in vivo.
Thus, quinine sulphate microparticles have the potential, especially, in treating visceral leishmaniasis.
American Psychological Association (APA)
Allotey-Babington, Grace Lovia& Amponsah, Seth Kwabena& Nettey, Thomas& Sasu, Clement& Nettey, Henry. 2020. Quinine Sulphate Microparticles as Treatment for Leishmaniasis. Journal of Tropical Medicine،Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1191305
Modern Language Association (MLA)
Allotey-Babington, Grace Lovia…[et al.]. Quinine Sulphate Microparticles as Treatment for Leishmaniasis. Journal of Tropical Medicine No. 2020 (2020), pp.1-9.
https://search.emarefa.net/detail/BIM-1191305
American Medical Association (AMA)
Allotey-Babington, Grace Lovia& Amponsah, Seth Kwabena& Nettey, Thomas& Sasu, Clement& Nettey, Henry. Quinine Sulphate Microparticles as Treatment for Leishmaniasis. Journal of Tropical Medicine. 2020. Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1191305
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1191305